Rahul Aggarwal
Rahul Aggarwal
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-17 | NCT05011188 | |
| Imaging of Solid Tumors Using 18F-TRX | Clear-cell metastatic renal cell carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, castration-resistant prostate carcinoma, epithelial neoplasm, glioma, kidney cancer, kidney disorder, male reproductive organ cancer, male reproductive system disorder, malignant glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, renal cell carcinoma, urinary system disorder | Recruiting | Phase 1 | 2026-07-23 | NCT06942104 | |
| ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, castration-resistant prostate carcinoma, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-07-23 | NCT04471974 | |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, kidney cancer, kidney disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, renal cell carcinoma, transitional cell carcinoma, urinary system disorder, uterine disorder | Active, not recruiting | Phase 2 | 2026-04-23 | NCT03682289 | |
| 64Cu-GRIP B in Patients With Advanced Malignancies | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Male Urogenital Diseases, Neoplasms by Site, Nutritional and Metabolic Diseases, Skin Diseases, Metabolic, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, congenital generalized lipodystrophy, hereditary disease, inborn errors of metabolism, kidney cancer, kidney disorder, lipodystrophy, male reproductive organ cancer, male reproductive system disorder, metabolic disease, neoplasm, prostate cancer, prostate disorder, skin disorder, urethra neoplasm, urethral disorder, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-03-17 | NCT05888532 |